Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-4 of 4 for your search:
Drug:
LMB-2 immunotoxin
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase II Study of Recombinant LMB-2 Immunotoxin and Peptide Vaccination Comprising gp100:209-217 (210M) Antigen, MART-1:27-35 Antigen, and Montanide ISA-51 in Patients With Progressive Unresectable Metastatic Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-06-C-0041
, 7542, NCI-7542, NCI-P6702, NCT00295958
2.
Phase I Study of the Recombinant Immunotoxin LMB-2 in Patients With Tac-Expressing Leukemias and Lymphomas
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-96-C-0064F
, NCI-T95-0042N, T95-0042, NCT00002765
3.
Phase I Study of LMB-2 Immunotoxin in Pediatric Patients With CD25-Positive Relapsed or Refractory Leukemia or Lymphoma
Phase:
Phase I
Type:
Treatment
Status:
Completed
Age:
6 months to 21 years
Sponsor:
NCI
Protocol IDs:
NCI-04-C-0168
, NCI-5903, 5903, NCT00085150
4.
Pilot Study of Fludarabine Phosphate and Cyclophosphamide Followed By LMB-2 Immunotoxin in Patients With CD25-Positive Hodgkin's Lymphoma
Phase:
No phase specified
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-06-C-0240
, NCI-P6761, 7835, NCI-7835, NCT00389506
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute